Welcome to TAGRISSO® (osimertinib) Connect
This is a promotional website developed by AstraZeneca, which will discuss AstraZeneca products.
Osimertinib as a monotherapy is indicated for:
- The adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations
- The first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations
- The treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC
On this site you will find information and a range of materials to support you in the management of patients with EGFR mutation-positive non-small cell lung cancer (NSCLC).